OSL oncosil medical ltd

5.69%

$1.16

Ann: CE Mark Update, page-375

First 375 Last

Share
Profile

Follow
Abdi70

615 Posts.

173

17/03/20

18:19

Post #: 43545048
Share

Originally posted by milsha77: ↑

Merlin, gekkowolf: nope those examples can’t be applied here . It’s very likely those two devices you cite used evidence of equivalence to other devices already on market, which is allowed under CE directive, to get away with providing limited data and get CE. It’s in the MEDDEV guidance my friends. There are already other atrial shunts and embolic protection devices available it seems. But for oncosil device, no suitable equivalent. (And no, SRX SIRT isn’t the equivalent).

so no change here, despite the claims osl has pumped out over time about panco and which have been swallowed by the more gullible sections of the market, the osl device’s efficacy remains unproven - this is FACT. Only safety is reasonably confirmed. Every single efficacy endpoint in panco could have been 100% down to the strong chemo.

oh you’ll be pleased to know Celgene recently got their locally adv panc cancer chemo study published (Lancet , main author Professor Philip, can be found on line ). So lets get this right- Celgene gives 107 patients with local adv PC gemcit plus abraxane and gets 18.8 month median overall survival. Panco adds the oncosil device to gemcit plus abraxane and gets ....16 month survival. It’s a real head- scratcher! Wonder if this has caught the attention of BSI?

Expand

Nice find milsha77,

but you know what a critical audience we have here... so here's a link to the "JOURNAL ARTICLE" (I haven't forgotten Gekko):

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30327-9/fulltext

Milsha77, stop scratching your head!
the CI in this trial was 18.8 (15.0 - 24.0). In other words there was no difference between the two trials. Oncosil quoted BSI as informing them that there was "insufficient benefit"... so I'm sure they're up to date with the literature.

OSL Price at posting: 9.2¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

First 375 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.16		Change -0.070(5.69%)		Mkt cap ! $16.49M

Open	High	Low	Value	Volume
$1.25	$1.25	$1.11	$72.36K	60.96K

Buyers (Bids)

No.	Vol.	Price($)
1	9286	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.18	412	1

View Market Depth

No.	Vol.	Price($)
1	9286	1.160
1	2126	1.150
1	7500	1.080
2	19761	1.050
1	2500	1.030

Price($)	Vol.	No.
1.180	412	1
1.200	8677	1
1.245	2418	1
1.250	46027	1
1.300	1500	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

OSL (ASX) Chart

Ann: CE Mark Update, page-375

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: CE Mark Update, page-375

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News